Resonance Health’s shares have observed a remarkable 35.4% surge, reaching a value of A$0.088.

This marks the most substantial intraday percentage increase since December 30, 2021.

The stock achieved its highest rate since June 3, 2022.

The company announced that it has entered a contract with Sun Pharmaceutical Industries to offer clinical research organization (CRO), laboratory analysis and imaging services for the clinical trial of Sun Pharmaceutical’s new drug compound in Australia.

The value of this clinical trial agreement is estimated at A$6.33 million in revenue over the coming 18 months.

As of the last close, the company shares had risen by 8.3% this year.

Resonance Health (ASX:RHT) is a medical technology company that provides health-care solutions to improve patient outcomes.